Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Epistemonikos ID: 1c8f5dc8e9bbe30af40b726a7a2e93aa12183c1a
First added on: Feb 19, 2024